Non-small Cell Lung Cancer (NSCLC) in Srinagarind Hospital: 2000-2010, Hospital Based
Non-small Cell Lung Cancer (NSCLC) in Srinagarind Hospital: 2000-2010, Hospital Based
复制标题
Srinagarind 医院的非小细胞肺癌 (NSCLC)：2000-2010 年，以医院为基础
DOI：
--
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
K. Wirasorn
中科院分区：
文献类型：
--
作者：
Wiyada Punjaruk;Krittika Suwanrungruag;K. Wirasorn
背景和目标：肺癌是世界范围内最常见的恶性肿瘤，尤其是非小细胞肺癌（NSCLC），在许多国家是导致死亡的主要原因。本研究的目的是回顾2000-2010年在Srinagarind医院接受治疗的NSCLC患者的特征。此外，本研究还列出了生存时间。研究方法：本研究纳入了2000年1月1日至2010年12月31日在Srinagarind医院登记的所有新发NSCLC癌症病例。我们的数据来自孔敬癌症登记处。分析患者特点及生存期。结果：Srinagarind医院2000-2010年期间研究的新发NSCLC病例数量在男性和女性NSCLC患者中相当稳定。在整个研究期间，NSCLC男性病例数约为女性病例数的2倍。新发NSCLC病例与总癌症病例的比例为1：11.91（49，763例病例中的4，176例）或8.39%。NSCLC在男性中的发生率高于女性（2.57：1）。首次诊断NSCLC时，男性平均年龄为60岁，女性为57岁。一半的非小细胞肺癌患者通常表现为IV期，其次发现III期（19.76%）。所有NSCLC患者的总体中位生存时间为7.92个月（95%置信区间（CI），7.42，8.58; p值< 0.05）。此外，I-IV期患者的总体中位生存时间分别为39.72、21.84、11.26和6.24个月。结论：非小细胞肺癌的发病呈加速增长的趋势，且患者多为晚期，生存率低。
Background and Objectives: Lung cancer is the most common cancer occurred worldwide especially non-small cell lung cancer (NSCLC) and it is the leading cause of death in many countries . The aim of this study is to review the characteristics of NSCLC patients who received treatment in Srinagarind Hospital during 2000-2010. Additionally, survival time was also presented in this study. Methods: All new NSCLC cancer cases registered in Srinagarind Hospital between January 1 st , 2000 and December 31 st , 2010 were included in this study. Our data were obtained from the Khon Kaen Cancer Registry. The characteristics of patients and survival time were analysed. Results: The number of new NSCLC cases studied during 2000-2010 in Srinagarind Hospital was fairly constant in both male and female NSCLC patients. Numbers of NSCLC male cases were approximately 2 folds higher than female cases throughout the study period. The ratio of new NSCLC cases per total cancer cases was 1:11.91 (4,176 of 49,763 cases) or 8.39%. NSCLC was found in male at a higher frequency compared to female (2.57:1). The mean age at primary diagnosis of NSCLC was 60 years in male and 57 years in female. Half of NSCLC patients commonly presented with stage IV and stage III of disease was secondly found (19.76%). Overall median survival time of all NSCLC patients was 7.92 months (95% confidence interval (CI), 7.42, 8.58; p value < 0.05). Additionally, the overall median survival times of patients with stage I-IV were 39.72, 21.84, 11.26, and 6.24 months, respectively. Conclusions: The trends of NSCLC are accelerating increasing and NSCLC patients usually presented with advanced stages of diseases resulting in poor survival rate.